FDA Joint Meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety, and Risk Management Advisory Committee and Pediatric Advisory Committee

The Committees will discuss the benefit risk assessment of long acting beta-2 adrenergic agonists for the treatment of asthma in adults and children.

MORE ON THIS TOPIC